{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:24:16Z","timestamp":1780583056015,"version":"3.54.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Alcohol use disorder (AUD) represents a significant global health burden, characterized by high relapse rates and limited treatment options. Valproic acid, primarily used as an anticonvulsant and mood stabilizer, has been suggested as a potential therapeutic agent for AUD, particularly in patients with coexisting psychiatric conditions. This study systematically analyses clinical trials from <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link> to evaluate the efficacy of valproic acid in treating AUD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic search of <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link> was conducted to identify clinical trials involving valproic acid in the management of substance use disorder (SUD). A total of 3,822 studies related to SUD were initially identified. Screening for anticonvulsant use narrowed this to 96 trials, and four completed studies specifically involving valproic acid and AUD were included in the final analysis. Key outcomes related to relapse rates, substance use reduction, mood stabilization, and withdrawal symptoms were examined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The included studies focused on various conditions, including alcohol dependence, bipolar disorder with substance abuse, traumatic brain injury with alcohol use, and medication-overuse headache. Valproic acid demonstrated potential benefits in reducing alcohol consumption, stabilizing mood, and managing withdrawal symptoms in specific subpopulations. However, relapse rates remained high in some trials, indicating limited long-term efficacy. Secondary outcomes showed improvements in psychiatric symptoms, though adverse effects such as sedation and gastrointestinal disturbances were noted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Valproic acid shows potential as a therapeutic option for managing AUD, particularly in individuals with coexisting psychiatric conditions or complex clinical profiles. While the drug showed some efficacy in reducing substance use and stabilizing mood, the overall impact on long-term abstinence remains uncertain. Further research is needed to better define the role of valproic acid in AUD treatment and to identify patient populations that may benefit most from its use.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1503035","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T05:24:58Z","timestamp":1745558698000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the efficacy of valproic acid in alcohol use disorder: a systematic analysis of clinical trials from ClinicalTrials.gov"],"prefix":"10.3389","volume":"16","author":[{"given":"Fahad S.","family":"Alshehri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3389\/fpsyt.2019.00228","article-title":"Use of gabapentin in the treatment of substance use and psychiatric disorders: a systematic review","volume":"10","author":"Ahmed","year":"2019","journal-title":"Front. Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.brainres.2014.07.051","article-title":"The histone deacetylase (HDAC) inhibitor valproic acid reduces ethanol consumption and ethanol-conditioned place preference in rats","volume":"1583","author":"Al Ameri","year":"2014","journal-title":"Brain Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"594612","DOI":"10.3389\/fnins.2020.594612","article-title":"On the digital psychopharmacology of valproic acid in mice","volume":"14","author":"Bass","year":"2020","journal-title":"Front. Neurosci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","article-title":"Medication treatment of opioid use disorder","volume":"87","author":"Bell","year":"2020","journal-title":"Biol. Psychiatry"},{"key":"B5","article-title":"Substance use and substance use disorder by industry","author":"Bush","year":"2016"},{"key":"B6","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/hep.30358","article-title":"Diagnosis and treatment of alcohol use disorder in patients with end-stage alcoholic liver disease","volume":"70","author":"Caputo","year":"2019","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2174\/1570159X21666230224102318","article-title":"Pharmacological strategies for bipolar disorders in acute phases and chronic management with a special focus on lithium, valproic acid, and atypical antipsychotics","volume":"21","author":"Carli","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3390\/brainsci14030294","article-title":"A narrative review of current and emerging trends in the treatment of alcohol use disorder","volume":"14","author":"Celik","year":"2024","journal-title":"Brain Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1592\/phco.21.20.1549.34480","article-title":"Pancreatitis associated with valproic acid: a review of the literature","volume":"21","author":"Chapman","year":"2001","journal-title":"Pharmacotherapy"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/sj.mp.4001893","article-title":"Valproate protects dopaminergic neurons in midbrain neuron\/glia cultures by stimulating the release of neurotrophic factors from astrocytes","volume":"11","author":"Chen","year":"2006","journal-title":"Mol. Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1218737","DOI":"10.3389\/fncir.2023.1218737","article-title":"GABAergic signaling in alcohol use disorder and withdrawal: pathological involvement and therapeutic potential","volume":"17","author":"Dharavath","year":"2023","journal-title":"Front. Neural Circuits"},{"key":"B12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/neurolint14010004","article-title":"Naltrexone implant for opioid use disorder","volume":"14","author":"Edinoff","year":"2021","journal-title":"Neurol. Int."},{"key":"B13","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s12028-020-01061-8","article-title":"Alcohol withdrawal syndrome in neurocritical care unit: assessment and treatment challenges","volume":"34","author":"Farrokh","year":"2021","journal-title":"Neurocrit Care"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s00787-020-01602-8","article-title":"Psychiatric morbidity, somatic comorbidity and substance use in an adolescent psychiatric population at 3-year follow-up","volume":"30","author":"Gardvik","year":"2021","journal-title":"Eur. Child. Adolesc. Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1177\/8755122517714491","article-title":"Treatment of severe alcohol withdrawal: a focus on adjunctive agents","volume":"33","author":"Guirguis","year":"2017","journal-title":"J. Pharm. Technol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1468-2982.2008.01711.x","article-title":"Management of medication overuse headache: 1-year randomized multicentre open-label trial","volume":"29","author":"Hagen","year":"2009","journal-title":"Cephalalgia"},{"key":"B17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1600-0404.2011.01542.x","article-title":"A randomized controlled trial on medication-overuse headache: outcome after 1 and 4 years","volume":"124","author":"Hagen","year":"2011","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"B18","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1001\/jamapsychiatry.2021.1271","article-title":"Use of medications for alcohol use disorder in the US: results from the 2019 national survey on drug use and health","volume":"78","author":"Han","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.mayocpiqo.2021.01.013","article-title":"Naltrexone initiation in the inpatient setting for alcohol use disorder: a systematic review of clinical outcomes","volume":"5","author":"Kirchoff","year":"2021","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes"},{"key":"B20","doi-asserted-by":"publisher","first-page":"115951","DOI":"10.1016\/j.biopha.2023.115951","article-title":"Drug addiction and treatment: an epigenetic perspective","volume":"170","author":"Koijam","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/01.alc.0000113413.37910.d7","article-title":"Pharmacological treatment of alcohol abuse\/dependence with psychiatric comorbidity","volume":"28","author":"Le Fauve","year":"2004","journal-title":"Alcohol Clin. Exp. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1080\/08897077.2015.1133472","article-title":"Potential medications for the treatment of alcohol use disorder: an evaluation of clinical efficacy and safety","volume":"37","author":"Litten","year":"2016","journal-title":"Subst. Abus"},{"key":"B23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1345\/aph.1G243","article-title":"Valproic acid management of acute alcohol withdrawal","volume":"40","author":"Lum","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","article-title":"Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?","volume":"108","author":"Maisel","year":"2013","journal-title":"Addiction"},{"key":"B25","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/molecules27010104","article-title":"Insights into structural modifications of valproic acid and their pharmacological profile","volume":"27","author":"Mishra","year":"2021","journal-title":"Molecules"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","article-title":"Adverse drug reactions induced by valproic acid","volume":"46","author":"Nanau","year":"2013","journal-title":"Clin. Biochem."},{"key":"B27","volume-title":"Substance use atlas 2021","year":"2023"},{"key":"B28","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1017\/s1092852900027346","article-title":"Mood stabilizers in the treatment of substance use disorders","volume":"15","author":"Perugi","year":"2010","journal-title":"CNS Spectr."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e210242","DOI":"10.1001\/jamanetworkopen.2021.0242","article-title":"Assessment of annual cost of substance use disorder in US hospitals","volume":"4","author":"Peterson","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"B30","article-title":"Valproic acid","author":"Rahman","year":"2020"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e208279","DOI":"10.1001\/jamanetworkopen.2020.8279","article-title":"Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders: a systematic review and meta-analysis","volume":"3","author":"Ray","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"B32","doi-asserted-by":"publisher","first-page":"S243","DOI":"10.1192\/j.eurpsy.2022.628","article-title":"Growing use of valproic acid in substance use disorders","volume":"65","author":"Rom\u00e3o","year":"2022","journal-title":"Eur. Psychiatry"},{"key":"B33","first-page":"679","article-title":"GABAergic system","volume-title":"Encyclopedia of molecular pharmacology","author":"Rudolph","year":"2022"},{"key":"B34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/archpsyc.62.1.37","article-title":"Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study","volume":"62","author":"Salloum","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1360-0443.2006.01592.x","article-title":"Comorbidity between substance use disorders and psychiatric conditions","volume":"101","author":"Schuckit","year":"2006","journal-title":"Addiction"},{"key":"B36","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/metabo13010134","article-title":"Therapeutic and toxic effects of valproic acid metabolites","volume":"13","author":"Shnayder","year":"2023","journal-title":"Metabolites"},{"key":"B37","doi-asserted-by":"publisher","first-page":"112021","DOI":"10.1016\/j.biopha.2021.112021","article-title":"Hidden pharmacological activities of valproic acid: a new insight","volume":"142","author":"Singh","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"B38","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s10822-020-00304-2","article-title":"Exploring the inhibitory activity of valproic acid against the HDAC family using an MMGBSA approach","volume":"34","author":"Sixto-Lopez","year":"2020","journal-title":"J. Comput. Aided Mol. Des."},{"key":"B39","doi-asserted-by":"publisher","first-page":"111137","DOI":"10.1016\/j.jpsychores.2022.111137","article-title":"The burden of somatic diseases among people with alcohol- and drug use disorders are influenced by mental illness and low socioeconomic status. A registry-based cohort study in Norway","volume":"165","author":"Skarstein","year":"2023","journal-title":"J. Psychosom. Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1159\/000363232","article-title":"Alcohol use disorders in opioid maintenance therapy: prevalence, clinical correlates and treatment","volume":"21","author":"Soyka","year":"2015","journal-title":"Eur. Addict. Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13722-023-00365-2","article-title":"Substance use disorder bridge clinics: models, evidence, and future directions","volume":"18","author":"Taylor","year":"2023","journal-title":"Addict. Sci. Clin. Pract."},{"key":"B42","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(15)00398-1","article-title":"The remarkable story of valproic acid","volume":"15","author":"Tomson","year":"2016","journal-title":"Lancet Neurol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1134\/s0022093023050228","article-title":"Molecular mechanisms of valproic acid action on signalling systems and brain functions","volume":"59","author":"Tursunov","year":"2023","journal-title":"J. Evol. Biochem. Physiology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s002210000443","article-title":"Molecular regulation of glutamate and GABA transporter proteins by valproic acid in rat hippocampus during epileptogenesis","volume":"133","author":"Ueda","year":"2000","journal-title":"Exp. Brain Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.2174\/1570159X20666220830154002","article-title":"Triple diagnosis of attention-deficit\/hyperactivity disorder with co-existing bipolar and alcohol use disorders: clinical aspects and pharmacological treatments","volume":"21","author":"Weiss","year":"2023","journal-title":"Curr. Neuropharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1503035\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T05:24:59Z","timestamp":1745558699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1503035\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":45,"alternative-id":["10.3389\/fphar.2025.1503035"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1503035","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"article-number":"1503035"}}